author-photo

Peter Sklar

Merck & Co.

43

Papers

2311

Citations

Citation Trend

Filter By

Papers (31) Sort By

Journal Conference Others

Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.

2021 Journal of Acquired Immune Deficiency Syndromes
Show All
- Source
- Cite
- Save
Citations (2)
Impact of HIV-1 Resistance-associated Mutations on Susceptibility to Doravirine: Analysis of Real-world Clinical Isolates.

2021 Antimicrobial Agents and Chemotherapy
Show All
- Source
- Cite
- Save
Citations (1)
1011. Efficacy and Safety of Doravirine in Treatment-Naïve Adults ≥50 Years Old With HIV-1

2020 Open Forum Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (0)
Effet de la doravirine sur le poids et l’indice de masse corporelle chez les adultes VIH-1 débutant un traitement antirétroviral

2020 Medecine Et Maladies Infectieuses
Show All
- Source
- Cite
- Save
Citations (0)
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.

2020 Journal of Acquired Immune Deficiency Syndromes
Show All
- Source
- Cite
- Save
Citations (2)
Changes in weight and body mass index with first-line doravirine-based therapy: a pooled analysis of three randomized controlled trials.

2020 AIDS
Show All
- Source
- Cite
- Save
Citations (8)
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

2019 Clinical Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (73)
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naïve HIV-1 Infected Adults with Transmitted Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance Mutations

2019 Journal of Acquired Immune Deficiency Syndromes
Show All
- Source
- Cite
- Save
Citations (12)
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

2018 The Lancet HIV
Show All
- Source
- Cite
- Save
Citations (76)
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease

2017 Neurology
Show All
- Source
- Cite
- Save
Citations (32)